The Trump administration says pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations and that it's expected to produce billions in savings for older adults. But the net prices unveiled Tuesday aren't what Medicare recipients will pay at their pharmacy counters because those final amounts will depend on each individual's plan and how much they spend annually on prescriptions. Health Secretary Robert F. Kennedy Jr. touted the deals as part of efforts to address affordability concerns. The negotiation program is mandated by law and began under the Biden administration.

Higher prices, less help and a government shutdown hang over health insurance markets as shoppers start looking for coverage this week. The annual enrollment window for millions of people to pick an individual plan opens Saturday. The federal government shut down this month as Democrats in Congress demanded negotiations to extend enhanced tax credits that have helped people buy coverage the past few years. Republicans say they won't negotiate until Democrats vote to reopen the government. Stuck in the middle are insurance shoppers, many of whom will be facing the biggest premium hikes they've seen in years.

Pricey prescriptions and nagging medical costs are swamping some insurers and employers, which means patients may start paying more next year. Health insurance will grow more expensive in many corners of the market in 2026, and some coverage may shrink. That could leave patients exposed to more costs for doctor visits and prescription coverage changes. Price changes could be especially stark in individual coverage marketplaces, where insurers also are predicting the end of some government support that helps people buy coverage. Expensive gene therapies and diabetes and obesity treatments are pressuring prescription coverage.

Supplies of high-demand obesity treatments are improving, but that doesn't mean they're easier to get. Many employers and health insurers are scaling back coverage of Wegovy or Zepbound and a key government program, Medicare, doesn't cover the drugs for obesity. Clouding the picture even further, some big employers are adding coverage. But their commitment isn't guaranteed. Treatment prices that can top hundreds of dollars monthly even after discounts make it hard for many to afford these drugs on their own. That makes the life-changing weight-loss that patients seek largely dependent on the coverage they have and how long it lasts.